BioNTech SE (22UA) - Total Assets
Based on the latest financial reports, BioNTech SE (22UA) holds total assets worth €21.34 Billion EUR (≈ $24.95 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See BioNTech SE (22UA) shareholders funds for net asset value and shareholders' equity analysis.
BioNTech SE - Total Assets Trend (2016–2024)
This chart illustrates how BioNTech SE's total assets have evolved over time, based on quarterly financial data.
BioNTech SE - Asset Composition Analysis
Current Asset Composition (December 2024)
BioNTech SE's total assets of €21.34 Billion consist of 83.5% current assets and 16.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 43.3% |
| Accounts Receivable | €1.46 Billion | 6.5% |
| Inventory | €283.30 Million | 1.3% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €790.40 Million | 3.5% |
| Goodwill | €380.60 Million | 1.7% |
Asset Composition Trend (2016–2024)
This chart illustrates how BioNTech SE's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 22UA company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioNTech SE's current assets represent 83.5% of total assets in 2024, an increase from 81.6% in 2016.
- Cash Position: Cash and equivalents constituted 43.3% of total assets in 2024, down from 77.9% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 2.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 6.5% of total assets.
BioNTech SE Competitors by Total Assets
Key competitors of BioNTech SE based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
BioNTech SE - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.12 | 7.33 | 2.75 |
| Quick Ratio | 7.02 | 7.21 | 2.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €13.61 Billion | €15.96 Billion | €1.06 Billion |
BioNTech SE - Advanced Valuation Insights
This section examines the relationship between BioNTech SE's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.28 |
| Latest Market Cap to Assets Ratio | 1.03 |
| Asset Growth Rate (YoY) | -2.1% |
| Total Assets | €22.53 Billion |
| Market Capitalization | $23.24 Billion USD |
Valuation Analysis
Above Book Valuation: The market values BioNTech SE's assets above their book value (1.03x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: BioNTech SE's assets decreased by 2.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for BioNTech SE (2016–2024)
The table below shows the annual total assets of BioNTech SE from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €22.53 Billion ≈ $26.34 Billion |
-2.07% |
| 2023-12-31 | €23.01 Billion ≈ $26.90 Billion |
-1.17% |
| 2022-12-31 | €23.28 Billion ≈ $27.22 Billion |
+47.05% |
| 2021-12-31 | €15.83 Billion ≈ $18.51 Billion |
+582.77% |
| 2020-12-31 | €2.32 Billion ≈ $2.71 Billion |
+190.68% |
| 2019-12-31 | €797.65 Million ≈ $932.53 Million |
+22.15% |
| 2018-12-31 | €652.99 Million ≈ $763.41 Million |
+74.26% |
| 2017-12-31 | €374.71 Million ≈ $438.08 Million |
-3.91% |
| 2016-12-31 | €389.96 Million ≈ $455.90 Million |
-- |
About BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which… Read more